Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
A2IDD5
UPID:
CCD78_HUMAN
Alternative names:
hsCCDC78
Alternative UPACC:
A2IDD5; B4DNY4; B4E1U6; Q05BY7; Q05CA0; Q6T2V5; Q6ZR33; Q8IUR3; Q8NAY7; Q96S12
Background:
Coiled-coil domain-containing protein 78 (hsCCDC78) plays a pivotal role in cell biology as a component of the deuterosome. This structure is crucial for de novo centriole amplification in multiciliated cells, enabling the generation of over 100 centrioles. Its function is essential for centriole amplification and CEP152 localization, occurring in terminally differentiated multiciliated cells outside of the S phase.
Therapeutic significance:
The association of hsCCDC78 with Myopathy, centronuclear, 4, a congenital muscle disorder, underscores its clinical importance. Understanding the role of hsCCDC78 could open doors to potential therapeutic strategies for this progressive muscular weakness and wasting disease.